First Tracks Biotherapeutics (Ticker: TRAX) is a forward-thinking biotechnology company focused on developing targeted therapeutics for chronic diseases, utilizing advanced research methodologies and proprietary technologies. The firm is committed to addressing significant unmet medical needs by prioritizing both the safety and efficacy of its innovative drug candidates. As TRAX progresses through clinical trials, it is actively pursuing strategic partnerships to enhance its development pipeline and expand its market footprint, reflecting its dedication to improving patient outcomes within the biopharmaceutical sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-139.61M |
| EBITDA | $-169.08M |
| Operating Margin | 0.00% |
| Return on Equity | -48.90% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.77 |
| Price-to-Book | 9.00 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $35.73M |
| Float | $26.15M |
| % Insiders | 8.74% |
| % Institutions | 99.46% |
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TRAX and any ticker you trade — then tracks every position and per-strategy win rate.
